These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38562783)

  • 1. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease.
    Galasko D; Farlow MR; Lucey BP; Honig LS; Elbert D; Bateman R; Momper J; Thomas R; Rissman RA; Pa J; Aslanyan V; Balasubramanian A; West T; Maccecchini M; Feldman HH
    medRxiv; 2024 Mar; ():. PubMed ID: 38562783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease.
    Galasko D; Farlow MR; Lucey BP; Honig LS; Elbert D; Bateman R; Momper J; Thomas RG; Rissman RA; Pa J; Aslanyan V; Balasubramanian A; West T; Maccecchini M; Feldman HH
    Alzheimers Res Ther; 2024 Jul; 16(1):151. PubMed ID: 38970127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.
    Maccecchini ML; Chang MY; Pan C; John V; Zetterberg H; Greig NH
    J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):894-902. PubMed ID: 22791904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients.
    Fang C; Hernandez P; Liow K; Damiano E; Zetterberg H; Blennow K; Feng D; Chen M; Maccecchini M
    J Prev Alzheimers Dis; 2023; 10(1):25-33. PubMed ID: 36641607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
    Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
    Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
    Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
    J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
    Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
    Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
    Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
    Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease.
    Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR
    J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
    Lahiri DK; Chen D; Maloney B; Holloway HW; Yu QS; Utsuki T; Giordano T; Sambamurti K; Greig NH
    J Pharmacol Exp Ther; 2007 Jan; 320(1):386-96. PubMed ID: 17003227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
    Novak G; Streffer JR; Timmers M; Henley D; Brashear HR; Bogert J; Russu A; Janssens L; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
    Alzheimers Res Ther; 2020 May; 12(1):58. PubMed ID: 32410694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial.
    Hernandez GD; Solinsky CM; Mack WJ; Kono N; Rodgers KE; Wu CY; Mollo AR; Lopez CM; Pawluczyk S; Bauer G; Matthews D; Shi Y; Law M; Rogawski MA; Schneider LS; Brinton RD
    Alzheimers Dement (N Y); 2020; 6(1):e12107. PubMed ID: 33344752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
    Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
    Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease.
    Nygaard HB; Wagner AF; Bowen GS; Good SP; MacAvoy MG; Strittmatter KA; Kaufman AC; Rosenberg BJ; Sekine-Konno T; Varma P; Chen K; Koleske AJ; Reiman EM; Strittmatter SM; van Dyck CH
    Alzheimers Res Ther; 2015; 7(1):35. PubMed ID: 25874001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.
    van Dyck CH; Mecca AP; O'Dell RS; Bartlett HH; Diepenbrock NG; Huang Y; Hamby ME; Grundman M; Catalano SM; Caggiano AO; Carson RE
    Alzheimers Res Ther; 2024 Jan; 16(1):20. PubMed ID: 38273408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.